ASCO GU 2023

Robust DFS benefit, but lack of OS data leaves open questions

New updates on immunocheckpoint inhibitors and ADCs - which therapy for which patient?

Bladder preservation strategies - promising data but no change in SoC yet?!

Pembro for HR NMIBC

Benefit of neoadjuvant pembro for CE and CI patients

Re-shaping bladder cancer treatment

Final overall survival

PD-1 as combo in 1st line

Atezo monotherapy for mUC

No change in SoC, but new genomic predictors for EV outcome

Final OS data show no significant benefit for chemo plus ICI

Urothelial cancer highlights from ASCO GU23

No final OS difference - but subgroups may benefit from Atezolizumab

Update / German Real World Data M1 BC

IMvigor130: final OS

The bladder cancer highlights of ASCO GU

Urothelial cancer - hidden gems of the poster session

Impressive DFS with adjuvant Nivo in biomarker-positive patients

New data for pembro in HR NIMBC

Checkpoint inhibition in adjuvant therapy

NMIBC highlights from ASCO GU23

3 yrs outcome of Nivo for adjuvant therapy

Pembrolizumab in HR NIMBC

Exciting survival data for adjuvant NIVO

Refinando el tratamiento del cancere vejiga

The bladder cancer highlights of ASCO GU

Επισημάνσεις για τον καρκίνο του ουροθηλίου από την ASCO GU23

PARPi are effective in PCa - which subgroups benefits most?

Los aspectos más destacados del ASCO GU 2023 en cáncer de vejiga

BCG yanıtsız yüksek riskli KİOMK tedavisinde Pembrolizumab

Triplet combination - all-comer therapy or high risk high volume only? How do we identify the patients who benefit?

BRCA mutations in mCRPC - the importance of biomarkers in PCa! Why we need better testing and better understanding of therapy combinations!

Benefits and risks of precision medicine with PARPi

New ways to target androgen receptor signaling

Normal baseline testosterone level is a strong predictor of post-ADT recovery

ARASENS: triple independent of volume and risk

MMAI - a superior prognostic marker for high risk patients

mHSPC - new standard and more insights

ARASENS - post-hoc subgroup analysis

Doublet or all-in: the solution for all patients?

Benefit in all groups

Monotherapy is not any longer standard of care

Surgery vs. Radiation for N1 PCa: who wins?

Formula 509: Racing to a better straegy for radiotherapy

Controversy in ADT roundtable

PARP and testing

Intensification of salvage therapy in high risk settings

PARPi combination in mCRPC

PARPi combo: all-comer treatment for mCRPC

Propel - final OS

Rucaparib - the new player?

TALA ENZO with improved PFS in mCRPC

Rucaparib - ready for clinical practice in BRCAmut patients

PARPi combo approval for all-comers - balancing benefit of treamtent vs. side effects is crucial

TALA in 1st line for all patients with mCRPC

Encouraging results for Talazoparib

Tiebreaker for previous trials

Rucaparib: treatment option for biomarker-selected patients

PARPi are effective in PCa - which subgroup benefits most?

PARPi study with different design

PARPi & ARPi with wonderful data

miR371'in orşiektomi sonrası tedavi seçimini yönlendirmekteki yüksek doğruluğu

RP sonrası kurtarma RT ile GnRH Analog ABİ APA kombinasyonu, kurtarma RT ve GnRH analog tedavisinden daha iyi PFS sağlar mı?

edavi öncesi normal testosteron seviyesi ADT sonrası testosteron geri dönüşü için güçlü bir prediktördür

PARPi & ARPi με υπέροχα δεδομένα

Ny PARP hämmar studie med anna design

Lokalize prostat kanserinde cerrahi ile SBRT karşılaştıran faz-3 randomize kontrollü çalışma

TALA ENZA kombinasyonu ile mKDPK olan hastalarda daha iyi progresyonsuz sağkalım

MMAI- Yüksek riskli prostat kanserinde üstün bir prognostik belirteç

Nya vägar att blockera androgenreceptor signalering

Novel updates on cabozantinib in advance RCC

Theranostics in RCC - usefull tools for ccRCC?!

Updated data of CheckMate 9ER - impact on real-world therapy

Reassuring update of CM9ER with longer follow up

Zircon-PET in RCC

First prospective data on 2nd line therapy after IO combination in mRCC

Longer FU confirms significant benefit of Nivo-Cabo, Cabo effective post IO first line

Hypothesis-generating differences in risks groups

Outcomes of patients with brain metastases treated with first-line therapies

New therapy choices for renal cell cancer patients

microbiom & CPI perspectives

Refining prediction of stage I seminoma

High accuracy of miR371 to guide treatment selection after orchiectomy

Mejorando la estimacion pronostica en Seminoma Estadio I